Tag: Biopharma
-

AstraZeneca and Bristol Myers Squibb Explore a $400 Billion Pharma Megadeal
AstraZeneca and Bristol Myers Squibb have reportedly explored a potential $400 billion merger. While no deal has been announced, the discussions highlight how U.S. expansion, portfolio diversification and long-term growth are reshaping strategic priorities across the global pharmaceutical industry.
-

Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-

Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.